PPARG and metabolic disease: These data suggest new therapeutic strategies using PPARγ ligands against fungal infections in immunocompromised hosts and during metabolic diseases, because they increase the innate immune response by enhancing the expression of both the MR and Dectin-1 that are heavily involved in the recognition and elimination of non-opsonized C.albicans.